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28 and were not evaluable for engraftment. Primary graft
failure occurred in 15 pts (35%) and 6 pts received a second
UCBT (only one pt is alive). Two other pts are alive with
autologous recovery (Osteopetrosis). Partial engraftment
(ANC 	 500/ul) occurred in 6 pts and all of them died. Acute
GVHD grade II-IV occurred in 15/28 pts (II: 2 pts, III: 8 pts;
IV: 5 pts) and C-GVHD in 11/20 pts (3 limited; 8 extensive).
Mucositis grade II-IV: 26 pts (III: 15 pts; IV: 3 pts). Arterial
hypertension and viral infections were also frequent complications.
VOD occurred in 4 pts (2 moderate; 1 severe). TRMwas very high in
this group reaching 46% (23 pts). Twenty-eight pts died in a median
of 38 days after UCBT (range 4–226). Main causes of death: infec-
tions: 20 pts (aggressive bacterial, fungal, and toxoplasmosis infec-
tions); bleeding: 3 pts; GVHD: 4 pts; and other: 1 pt. More than 70%
of our pts have bone marrow failures or osteopetrosis and this may
explain the high incidence of rejection and transplant relatedmortality
in this group of pts. Acute and chronic GVHD occurred with more
severity than expected for UCBT. We postulate that viral or other
infectious agents frequently found in our pts prior to transplant may
exacerbate this complication.
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STEM CELL TRANSPLANTATION IN 40 PTS WITH FANCONI ANEMIA
(FA): EXCELLENT SURVIVAL AND LOW TOXICITY FOR PTS WITH A
RELATED HLA IDENTICAL DONOR
Bonﬁm, C.1, Bitencourt, M.1, Funke, V.1, Setubal, D.1, Ruiz, J.1,
Seber, A.2, Pilonetto, D.1, Medeiros, C.R.1, Zanis-Neto, J.1,
Pasquini, R.1 1. Federal University of Parana, Curitiba, PR, Brazil; 2.
Instituto de Oncologia Pediatrica EPM, Sao Paulo, SP, Brazil.
SCT is the treatment of choice for FA patients (pts). These pts are
particularly hypersensitive to alkylating agents and radiation. In order
to decrease toxicity and maintain engraftment we have progressively
decreased the dose of CY during the last 20 years. In this study we
report our experience using the dose of CY 60 mg/kg in 40 pts
transplanted between 07/99–04/05. Median age : 9 years (5–29).
Previous blood transfusions: 0–101 (M: 5UI). Previous treatment with
androgens: 15/40 pts. All pts had pancytopenia and received either
unmanipulated bone marrow (39 pts) or cord blood (1 pt) from HLA
identical donors (siblings: 33 pts, other related: 7 pts). Preparatory
regimen consisted of CY 15 mg/kg/day  4. GVHD prophylaxis:
cyclosporine and methotrexate. TNC infused: 0, 97- 7, 3  108/kg
(M: 4, 05). The regimen was well tolerated with no transplant related
mortality (TRM). Thirty-eight pts (95%) are alive and well between
179–2250 days after SCT (M: 872 days). Median time to ANC
	500/ul: 19 days (11–57) and to platelets 	20.000/ul: 21 days (14–
57). Mucositis grades II–IV occurred in 92% of pts (II: 10 pts; III: 25
pts, IV: 1 pt). Mild VOD: 2 pts. Arterial hypertension was a frequent
complication. A-GVHD grade II-III occurred in 4/39 pts and C-
GVHD (extensive) in one pt. Primary graft failure (GF) occurred in
one pt (HLA identical sibling, 11 previous blood transfusions). He
received a second BMT from the same donor with no engraftment
and then a third BMT from another HLA identical sibling. He is now
187 days after BMT, independent of blood transfusion but with a slow
hematological recovery. Four pts (donors: 2 other related and 2
siblings) had a late GF on day 156, 202,  287, and 365 after
SCT. Three pts received a second SCT from the same donors and
they all engrafted. Two pts are alive and well with normal hemato-
logical counts on D 538 and 1203 after second SCT. Two pts
died: 1 after second SCT (day 98) due to A-GVHD, infection, and
cerebral venous sinus thrombosis. The other pt died on day918 due
to infections and complications related to rejection (29 years, 101
previous blood transfusions). We conclude that the use of CY 60
mg/kg in the preparatory regimen led to a better survival, no trans-
plant related mortality, and low incidence of both acute and chronic
GVHD. Graft failure occurred in 5 pts but 3 pts were rescued with
another transplant. This regimen can be offered safely to pts with
Fanconi anemia who have a related HLA identical donor.
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SINGLE CENTER EXPERIENCE OF UNRELATED UMBILICAL CORD
BLOOD TRANSPLANTATION (UCBDT) FOR ACUTE MYELOID LEUKEMIA
(AML) IN 97 PEDIATRIC PATIENTS: IMPACT OF DISEASE STATUS AND
CYTOREDUCTIVE REGIMEN
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Martin, P.L.1, Carter, S.2, Kurtzberg, J.1 1. Pediatric Blood and
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Banked, unrelated donor umbilical cord blood (UCB) increases
access to transplant by providing a source of hematopoietic stem
cells for patients (pts) lacking a family donor. We present outcomes
of 97 pediatric (ped) AML pts transplanted from 1995–2005. At
transplant, 51 pts were in Relapse or Refractory (RR) disease while
46 were in CR1/2 (CR). By low resolution HLA A/B  high-
resolution DRB1 typing, UCB units transplanted to RR pts were
3/6 (18%), 4/6 (45%), 5/6 (31%), or 6/6 (6%) matched and those
to CR pts were 4/6 (67%) or 5/6 (33%). The median age of RR and
CR pts was 8.4 and 9.4 years. Ethnic minorities comprised 35.3%
of RR and 34.8% of CR pts. Thirteen RR and 2 CR had prior auto-
or allo-transplants. The median total nucleated cell (TNC) doses
infused in RR and CR pts were 4.4 and 3.8  107/kg. All pts
received myeloablative regimens. RR pts receiving Melphalan con-
taining regimens (Bu/Mel/ATG or Flu/Mel/ATG or TBI/Mel/
ATG) were grouped as RR_Melve (n  33) and the rest receiving
TBI/Cy/ATG as RR_Melve (n  18). CR pts receiving TBI
containing regimens (TBI/Cy/ATG or TBI/Mel/ATG) were
grouped as CR_TBIve (n  29) and the rest receiving Bu/Mel/
ATG or Flu/Mel/ATG or Flu/Bu/Mel/ATG as CR_TBI-ve (n 
17). GVHD prophylaxis was Cyclosporinemethylprednisone in
94.8% The TNC dose, HLA match level, age, minority propor-
tion, and GVHD prophylaxis were similar between the RR and CR
pts. The probabilities of overall survival (OS) were estimated by
Kaplan-Meier analysis and compared using log-rank test. The 3
year probability of OS in the RR and CR was 28% and 48%.
AGVHD (Grade 2–4) was seen in 21.6% of RR and 21.7% of CR
pts and CGVHD in 6% and 7% of RR and CR pts. Deaths were
due to relapse, infection, and organ failure Within RR and CR the
impact of cytoreductive regimen was signiﬁcant. Three year prob-
ability of OS in CR_TBIve was signiﬁcantly higher (60%) than of
CR_TBIve (28%) pts (P  .014). The 3 year probability of OS in
RR_Melve was higher (39%) than of RR_Melve (11%) but the
difference did not reach statistical signiﬁcance(P  .132). We
conclude that for ped pts with AML lacking a family donor, UCB
is an excellent source of hematopoietic stem cells for those in
remission as well as those with high risk relapsed or refractory
disease. Cytoreductive regimen inﬂuences outcomes in both
groups of pts with more favorable outcomes in CR pts prepared
with TBI containing regimens and in refractory/relapsed pts pre-
pared with melphalan containing regimens.
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EVALUATION OF SECOND TRANSPLANTS FOLLOWING GRAFT FAILURE
IN UMBILICAL CORD BLOOD TRANSPLANTATION (UCBT)
Merchant, M.1, Duerst, R.1,2, Olszewski, M.1, Huang, W.1,
Jacobsohn, D.1,2, Kletzel, M.1,2 1. Children’s Memorial Hospital, Chi-
cago, IL; 2. Robert H. Lurie Cancer Center, Feinberg School of Medicine,
Northwestern University, Chicago, IL.
Objective: To evaluate the results of second allogeneic trans-
plantation after UCBT failed to engraft. Methods: Between No-
vember 1995 and July 2005, 116 UCBT were carried out at
Children’s Memorial Hospital of which 18 required second trans-
plantation (from failure to engraft, or relapse). Ten patients with
graft failure following a myeloablative cytoreduction regimen sub-
sequently received another transplant of unrelated cord blood (n
7), matched sibling marrow (n  1), marrow from a haploidentical
sibling (n  1), or matched sibling peripheral stem cells (n  1).
Underlying diseases for these 10 patients included AML (n  4),
Thalassemia (n  2), and 1 each of Myelodysplasia, Fanconi ane-
mia, Osteopetrosis, and ALL. Preparative conditioning prior to the
second transplant included Fludarabine 120–150 mg/m2 (n  5);
VP, Cy (n  2), or ATG (n  1). The 2 Thalassemia patients
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received hematopoietic stem cells (HSC) from the original
matched sibling cord blood donor, without additional preparative
therapy.Results/Outcome:Details of the 10 patients are provided
in the table. Cell doses for the ﬁrst and second HSC transplant
were not signiﬁcantly different. HSC for the second transplant
were 3 to 6 antigen matches (median  4). Median time interval
between the 2 transplants was 7 weeks (range 4–13). Five patients
died from TRM 2 to 6 weeks after second transplant without
engraftment. Three patients engrafted Neutrophils (days 14,
28, 36) after a second unrelated UCBT, but died from TRM
2.5 to 13 weeks after second transplant. Two patients with UCBT
from matched siblings did engraft following transplantation of
additional HSC. Conclusions: Graft failure following unrelated
UCBT proved to be fatal underscoring the critical reliance on
engraftment when the HSC donor is unavailable for a repeat
transplant. Although 3 patients engrafted after a second UCBT,
fatal infections and complications of GVHD still prevailed. Wead-
vise proceeding to a second transplant sooner than the 7 weeks in
our patients as the shorter duration of aplasia might improve the
outcome (Table 1).
Table 1. Second Transplant for Graft Failure after UCBT
UCBT
no. 1
HSCT
no. 2 UCBT
Second HSCT
Source
Allo
PBSCT
Allo
BMT
N  10 10 7 1 2
Age at transplant
(mo)
23 25 24 15 31
Weight at
transplant (kg)
23.3 22 24 14.3 25
CD 34  cells/kg
 106
0.74 0.80 0.70 2.60 11.3
MNC/kg  108 0.47 0.76 0.59 2.9 1.6
Engraftment 0 5 3 1 1
Interval UCBT
to HSCT no. 2
(wks)
7 7 7 6
TRM, N 8 7 0 1
TRM, days post
HSCT no. 2
median (range)
34.5 (17–91) 40 (17–91) 0 21
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REDUCED INTENSITY (RI) ALLOGENEIC CORD BLOOD HEMATOPOI-
ETIC CELL TRANSPLANTATION (Allo CBHCT) IN PEDIATRIC PATIENTS
WITH MALIGNANT AND NON-MALIGNANT DISEASES
Del Toro, G.1, Bradley, M.1, Satwani, P.1, Morris, E.1,
van de Ven, C.1, Cheung, Y.K.1, Yamashiro, D.1, Garvin, J.1,
Bhatia, M.1, Roman, E.1, Schwartz, J.1, Militano, O.1, Cooney, E.1,
Wolownik, K.1, Foley, S.1, Cairo, M.S.1 1Columbia University, College
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There is a signiﬁcant amount of morbidity and mortality follow-
ing myeloablative CBHCT (Gluckman et al, NEJM 1997; Rubin-
stein et al, NEJM 1998). RI conditioning may reduce regimen-
related mortality (RRM) and the late effects associated with
myeloablative regimens without increasing the risk of graft failure
in children and adolescents (Del Toro et al, BMT 2004). Engraft-
ment has been demonstrated in adult recipients with hematologic
malignancies following RI CBHCT (Chao et al, BBMT 2004). We
report the results in 22 pediatric recipients , 6 F:16 M, median age
6.5 years (0.4–21). Twenty-one received unrelated CBHC, with
HLA matching of 4/6 (n  14), 5/6 (n  5), 6/6 (n  2); 1 sibling
CBHC (6/6). Seventeen had malignant [HD (5), NHL (2), NB(4),
AML (2), MDS(3), CML (1)], and 5 had non-malignant [-thal (1),
HLH (2), WAS (1), SCD(1)] diseases. Poor-risk disease was de-
ﬁned as induction failure, PD, SD, CR3, and second allo HCT
(n  8). RI conditioning was ﬂudarabine-based (150–180 mg/m2)
with either busulfan (8 mg/kg)  rabbit ATG/alemtuzumab or
cyclophosphamide  etoposide/etoposide phosphate  ATG and
craniospinal radiation prophylaxis (n  1). GHVD prophylaxis:
tacrolimus and MMF (Osunkwo et al, BBMT 2004). Median TNC
count was 3.8  107/kg (0.92–10.82) and CD34 count was 2.2 
105/kg (0.34–6.95). The median day to WBC engraftment was
19.5 (1–47) and to platelet engraftment was 40 (6-170). Engraft-
ment was 72.7%. There were 6 primary graft failures (1 CML, 1
-Thal, 2 HLH, 1 MDS, and 1 AML). Of the 16 engrafted
patients, 15 achieved 90% or greater mixed-donor chimerism by
day 60. Five of 16 patients developed acute GVHD, with 3 devel-
oping grade III/IV acute GVHD. One patient developed extensive
chronic GVHD. There were 8 deaths (4 PD, 1RRM, 3 GVHD).
The probability of 3-year overall OS in all patients was 61%.
Despite a log less nucleated cells/kg with CB versus PB or BM
HCT, the 3-year OS in standard-risk malignancy pts was 90%.
The 1-yearr OS in poor-risk malignancy pts was 21%. The 1-yearr
OS in non-malignant diseases was 75%. In conclusion, RI Allo
CBHCT may result in more rapid hematopoietic reconstitution
while decreasing RRM compared to myeloablative CBHCT and
may be associated with high mixed-donor chimerism. Patients with
diseases such as CML, -Thal, and HLH may require increased
intensity of conditioning. Further follow-up is required to evaluate
the long-term effects following RI Allo CBHCT.
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NEUROBEHAVIORAL OUTCOME IN CHILDREN WITH MPS III (SANFIL-
IPPO SYNDROME) AFTER UNRELATED DONOR UMBILICAL CORD
BLOOD TRANSPLANTATION (UCBT)
Escolar, M.1, Lakshminayanaran, S.2, Szabolcs, P.2, Poe, M.1,
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Between September 1998 and June 2005, 15 children, ages 12–59
months, underwent (UCBT) for treatment MPS III (Sanﬁlippo
Syndrome, types A or B). Grafts were mismatched at 0 (n  1), 1
(n  10), or 2 (n  4) HLA loci. Preparative regimen consisted of
busulfan 40 mg/m 2/dose PO or 1 mg/kg/dose IV targeting a Css
of 600–900 ng/ml), cyclophosphamide 50 mg/kg per day  4, and
equine ATG 30 mg/kg per day  3. Cyclosporine and solumedrol
were used as GvHD prophylaxis. Donor engraftment occurred in
10/15 patients, although one additional patient engrafted after a
second transplant. Five patients with graft failure died within 8
months of transplant due to respiratory failure and viral infections
(Adenovirus, HSV), and one died 2.9 years post UCBT after
complications of GvHD. Six patients developed mild to moderate
acute GvHD and 3 patients had limited (2) or extensive (1) chronic
GvHD. All children were followed at baseline with brain auditory
evoked responses (BAER), head MRI, and neurodevelopmental
assessments. These were followed in surviving children every 6
months for 2 years and yearly thereafter. At initial evaluation, 10
children had abnormalities in BAER and all patients showed ab-
normalities in head MRI consisting of varying degrees of volume
loss that generally increased with age. EEGs were normal in 6/9
patients at pretransplant evaluation with the additional 3 demon-
strating generalized encephalopathy. These abnormal changes
were evident in 6/9 patients post transplant with 2 additional
patients developing epileptogenic activity. Two patients developed
hydrocephalus requiring VP shunt placement within 1 year of
transplant and 1 patient had subdural hematomas after minor head
trauma. Eight had mild to severe cognitive delay at the time of
transplantation. After transplant, 2 patients with mild delay con-
tinue to gain skills at a normal rate (follow-up 1.5–2.5 years, age
range 40–53 months at the last evaluation). Six patients have
stabilized at their pre-transplant level of functioning and 4 have
shown regression after transplantation. All patients, however, sleep
well, have improvement in behavior and general well being. We
conclude that UCBT stabilized neurocognitive function for at least
4 years at pre-transplant level in the majority of patients and
improved general well being of all surviving children with MPS III.
Effects of transplantation should be explored further in a larger
group of patients.
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